Inflammation, Skin Patents (Class 514/886)

Cross-Reference Art Collections

Topical treatment (Class 514/887)
  • Patent number: 6723345
    Abstract: Topical gelled compositions comprising an optional drug dispersed within a polymer matrix, methods of producing the same and treatments with the complex.
    Type: Grant
    Filed: November 7, 2001
    Date of Patent: April 20, 2004
    Assignee: L.A.M. Pharmaceutical Corp.
    Inventors: Alan Drizen, Peter Rothbart, Gary M. Nath
  • Patent number: 6716436
    Abstract: A cosmetic composition for slimming which includes, in combination with a cosmetically acceptable excipient, at least one compound having the formula (I) where R1 is a group bound by a peptidic bond and selected from the group consisting of a hydrogen atom, a hydroxyl group, an acyl group, acyloxy group and a substituted or unsubstituted aminoacid; R2 is a group bond by a peptidic bond and selected from the group consisting of a hydroxyl group, an amine group, an alkoxy group, an alkylamine group, a silyloxy group or a substituted or unsubstituted aminoacid; and n is 3 or 4.
    Type: Grant
    Filed: June 16, 2000
    Date of Patent: April 6, 2004
    Assignee: Exsymol S.A.M.
    Inventor: Marie-Christine Seguin
  • Patent number: 6709664
    Abstract: The present invention is directed to methods that can be used in the treatment of wounds, burns, and photodamaged skin. Methods can be used for both humans and animals and involve the administration of compositions containing selegiline and/or desmethylselegiline.
    Type: Grant
    Filed: August 8, 2002
    Date of Patent: March 23, 2004
    Assignee: Somerset Pharmaceuticals, Inc.
    Inventor: Mark G. Resnick
  • Patent number: 6692775
    Abstract: A gel formulation is combined with a bactericidal concentrate which is a liquid mixture of about 1000 parts by volume of ultra pure water having an electrical resistance of 16-26 megohms, total dissolved solids of less than 0.04 parts per million and a specific conductance of less than 0.10 mho with about 1.2 to 3 parts by volume of Willard Water as prepared in accordance with U.S. Pat. No. 3,893,943. The bactericidal liquid concentrate in the amount of 3.5 to 12 ml in one liter of gel formulation is applied directly to a skin surface area having a burn or other dermal lesion to protect the area from bacterial contamination.
    Type: Grant
    Filed: June 24, 2002
    Date of Patent: February 17, 2004
    Assignee: Aqua Med, Inc.
    Inventor: John D. Young
  • Patent number: 6692773
    Abstract: The invention relates to the use of one or more noble metals selected from silver, gold, platinum, and palladium but most preferably silver, in a nanocrystalline form, for the treatment of a hyperproliferative skin disorder or disease such as psoriasis. Among the noble metals, silver is preferred for such treatment. The nanocrystalline noble metal of choice may be used in the form of a nanocrystalline coating of one or more noble metals, a nanocrystalline powder of one or more noble metals, or a solution containing dissolved species from a nanocrystalline powder or coating of one or more noble metals.
    Type: Grant
    Filed: July 27, 2001
    Date of Patent: February 17, 2004
    Assignee: Nucryst Pharmaceuticals Corp.
    Inventors: Robert Edward Burrell, John Barrymore Wright, Kan Lam
  • Patent number: 6680304
    Abstract: The invention relates to novel disaccharides of formula (I), wherein R1 is selected from the group consisting of hydrogen, linear or branched (C1-C4) alkyl, phenylalkyl with less than ten carbon atoms and —COCH3; R2 is selected from the group consisting of hydrogen, —COCH3 and SO3M; R3 is selected from the group consisting of hydrogen, linear or branched (C1-C4) alkyl, phenylalkyl with less than ten carbon atoms, —COCH3 and y —COPh, Ph being phenyl; G is selected from amongst —COOR4 and —COOM, R4 is selected from the group consisting of hydrogen, (C1-C2)-alkyl and arylalkyl with less than sixteen carbon atom; A is selected from the group consisting of hydrogen, —SO3H, —SO3M and —COCH3; B is selected from the group consisting of hydrogen, —SO3H, —SO3M and —COCH3, wherein either A or B are necessarily either —SO3H or —SO3M, M being a an organic or metallic cation.
    Type: Grant
    Filed: January 10, 2003
    Date of Patent: January 20, 2004
    Assignee: Bioiberica, S.A.
    Inventors: Francisco Javier Vila Pahi, Francesc Flores Salgado, Ramon Ruhi Roura, Narcís Arnau Pastor
  • Patent number: 6676975
    Abstract: This application relates to a material which is suitable for the treatment of atopic disease, non-atopic eczema or psoriasis. The material can be extracted from a freeze-dried decoction of a mixture comprising the following Chinese herbs: Radix Ledebouriella, Fructus Tribuli, Herba Potentilla chinensis, Caulis Clematis armandii, Radix Rehmannia, Radix Glycyrrhiza, Radix Paeonia rubra, Cortex Dictamni radicis, Herba Lopatheri, Spica Schizonepetae. The material comprises one or more of those components present in the freeze-dried decoction which run with Rf values in the ranges 0.00 to 0.100, 0.167 to 0.300, 0.400 to 0.533, 0.700 to 0.833 or 0.900 to 0.967 if the freeze-dried decoction is diluted in aqueous solution and subjected to chromatography on a Whatman 2 cms×55 cms×3 mm cellulose strip for 10 hours using a solvent mixture of butanol, ethanol and water in the proportions 4:1:1.
    Type: Grant
    Filed: February 14, 2002
    Date of Patent: January 13, 2004
    Assignee: Phytotech Limited
    Inventors: Brian Anthony Whittle, Jonathan Brostoff, Yvette Latchman
  • Patent number: 6664406
    Abstract: The present invention relates to a nervonic acid derivatives of formula (I) CH3—(CH2)7—CH═CH—(CH2)13—C(O)—O—(CH2)3—OR  (I) wherein R is hydrogen (H) or a residue of a carboxylic acid; or a salt of the compound where R is H; or a bioprecursor, prodrug thereof. Those compounds wherein R is other than H have pharmacological activity, in particular anti-inflammatory and immunomodulatory effects. Those compounds wherein R is H can be used to prepare the pharmacologically active derivatives.
    Type: Grant
    Filed: August 19, 2002
    Date of Patent: December 16, 2003
    Assignee: Croda International PLC
    Inventors: Keith Coupland, Yann Raoul
  • Patent number: 6656969
    Abstract: The invention provides for methods of monitoring the proliferation of cultured prostate cancer cells in the presence of omega-3 fatty acids, methods of treating an individual with prostate cancer or at risk of developing prostate cancer, and methods of reducing the risk of recurrence of prostate cancer in an individual who had previously been treated for prostate cancer. Methods of the invention further include treating an individual with benign prostatic hyperplasia (BPH) with omega-3 fatty acids as well as methods of screening for compounds that inhibit the proliferation of prostate cancer cells. The invention provides for compositions and articles of manufacture containing omega-3 fatty acids in particular formulations, and omega-3 fatty acids with a second compound that also exerts an effect on the androgen receptor.
    Type: Grant
    Filed: September 20, 2001
    Date of Patent: December 2, 2003
    Assignee: Mayo Foundation for Medical Education and Research
    Inventor: Charles Young
  • Patent number: 6646011
    Abstract: The present invention relates to insect repellant compositions containing, based upon the total weight of the composition, from about 6 to about 30 percent by weight of insect repellant active material having functionality selected from ester, amide, urethane or combinations thereof; from about 5 to about 30 percent by weight of alcohol, and from about 1 to about 10 percent by weight of nonionic surfactant. The compositions of the invention exhibit reduced rates of degradation of the active material in solution and are less drying and irritating to sensitive skin.
    Type: Grant
    Filed: June 3, 1998
    Date of Patent: November 11, 2003
    Assignee: Johnson & Johnson Consumer Companies, Inc.
    Inventors: Danilo L. Lambino, Kennie U. Dee, Susan M. Niemiec
  • Patent number: 6645482
    Abstract: Compositions with synergistic anti-inflammatory effects in inflammatory diseases resulting from activation and consequent degranulation of mast cells and followed by secretion of inflammatory biomolecules from the activated mast cells, composed of a heavily sulfated, non-bovine proteoglycan such as shark cartilage chondroitin sulfate C, and one or more of a hexosamine sulfate such as D-glucosamine sulfate, a flavone such as quercetin, an unrefined olive kernel extract that increases absorption of these compositions in various routes of administration, S-adenosylmethionine, a histamine-1 receptor antagonist, a histamine-3 receptor agonist, an antagonist of the actions of CRH, caffeine, and a polyamine.
    Type: Grant
    Filed: December 27, 2002
    Date of Patent: November 11, 2003
    Inventor: Theoharis C. Theoharides
  • Patent number: 6645485
    Abstract: A process for treating inflammation in a joint whether heat, redness, pain, swelling and/or stiffness, and for increasing motion and increasing joint space and correcting malalignment, comprising the steps of dissolving a quantity of growth hormone (somatotropin), preferably in purified form, in a buffer solution, and injecting one time or multiple repeat times, a single dosage of the mixture of purified growth hormone and buffer solution into the joint of a body so as to initiate the treatment process.
    Type: Grant
    Filed: February 2, 2001
    Date of Patent: November 11, 2003
    Inventor: Allan R. Dunn
  • Patent number: 6641806
    Abstract: Compositions with synergistic anti-inflammatory effects in inflammatory diseases resulting from activation and consequent degranulation of mast cells and followed by secretion of inflammatory biomolecules from the activated mast cells, composed of a heavily sulfated, non-bovine proteoglycan such as shark cartilage chondroitin sulfate C, and one or more of a hexosamine sulfate such as D-glucosamine sulfate, a flavone such as quercetin, an unrefined olive kernel extract that increases absorption of these compositions in various routes of administration, S-adenosylmethionine, a histamine-1 receptor antagonist, a histamine-3 receptor agonist, an antagonist of the actions of CRH, caffeine, and a polyamine.
    Type: Grant
    Filed: December 27, 2002
    Date of Patent: November 4, 2003
    Inventor: Theoharis C. Theoharides
  • Patent number: 6635625
    Abstract: Compositions with synergistic anti-inflammatory effects in inflammatory diseases resulting from activation and consequent degranulation of mast cells and followed by secretion of inflammatory biomolecules from the activated mast cells, composed of a heavily sulfated, non-bovine proteoglycan such as shark cartilage chondroitin sulfate C, and one or more of a hexosamine sulfate such as D-glucosamine sulfate, a flavone such as quercetin, an unrefined olive kernel extract that increases absorption of these compositions in various routes of administration, S-adenosylmethionine, a histamine-1 receptor antagonist, a histamine-3 receptor agonist, an antagonist of the actions of CRH, caffeine, and a polyamine.
    Type: Grant
    Filed: December 27, 2002
    Date of Patent: October 21, 2003
    Inventor: Theoharis C. Theoharides
  • Publication number: 20030195141
    Abstract: Methods for inhibiting an inflammatory reaction in a mammal and pharmaceutical compositions are provided.
    Type: Application
    Filed: February 4, 2003
    Publication date: October 16, 2003
    Inventor: Ronald Mathison
  • Patent number: 6630442
    Abstract: A composition of glutathione and selenium, as a selenoamino acid or selenium yeast extract and an epidermal growth factor in a topical carrier and method of using the composition to reduce and repair skin damage, resulting from aesthetic (exfoliation and chemical peels) and surgical (laser and other therapies) procedures and other chemical and thermal burns to the cutaneous tissues.
    Type: Grant
    Filed: January 10, 1997
    Date of Patent: October 7, 2003
    Inventor: Theodore Hersh
  • Patent number: 6629835
    Abstract: A novel formulation is provided that serves to inhibit the inflammatory response in animals. The formulation comprises, as a first component an effective amount of a diterpene triepoxide lactone species and an effective amount of a second component selected from the group consisting of a diterpene lactone species and a triterpene species or derivatives thereof, and provides synergistic anti-inflammatory effects in response to physical or chemical injury or abnormal immune stimulation due to a biological agent or unknown etiology.
    Type: Grant
    Filed: August 1, 2001
    Date of Patent: October 7, 2003
    Assignee: MetaProteomics, LLC
    Inventors: John G. Babish, Terrence Howell, Linda Pacioretty
  • Patent number: 6623769
    Abstract: Lycopene and compositions comprised thereof, for example tomato plant extracts, are uniquely suited for treating, preventively and/or curatively, cutaneous signs of aging, in particular inhibiting damage to the skin and/or mucous membranes via inhibition of collagenases.
    Type: Grant
    Filed: October 10, 2000
    Date of Patent: September 23, 2003
    Assignee: Societe L'Oreal S.A.
    Inventors: Raluca Lorant, Lionel Breton, Christel Liviero
  • Patent number: 6610286
    Abstract: A method for treating IL-20 induced inflammation. An antagonist to IL-20 is administered to treat inflammation and associated diseases. The antagonist can be an antibody that binds to IL-20 or its receptor or a soluble receptor that binds to IL-20. Examples of such diseases are adult respiratory disease, psoriasis, eczema, contact dermatitis, atopic dermatitis, septic shock, multiple organ failure, inflammatory lung injury, bacterial pneumonia, inflammatory bowel disease, rheumatoid arthritis, asthma, ulcerative colitis and Crohn's disease.
    Type: Grant
    Filed: December 22, 2000
    Date of Patent: August 26, 2003
    Assignee: ZymoGenetics, Inc.
    Inventors: Penny Thompson, Donald C. Foster, Wenfeng Xu, James D. Kelly, Hal Blumberg, Yasmin A. Chandrasekher
  • Patent number: 6599914
    Abstract: Methods of inhibiting the generation of pro-inflammatory cytokines such as IL-4 and IL-13 in a human patient in need of such inhibiting are disclosed.
    Type: Grant
    Filed: April 24, 2001
    Date of Patent: July 29, 2003
    Assignee: Schering Corporation
    Inventors: Robert P. Schleimer, John Schroeder, William Kreutner
  • Patent number: 6596704
    Abstract: Compositions for the treatment of wounds and skin injuries are described. The compositions, which include gellan gum, increases in viscosity once applied to the wound to form an immobile gel. The composition may be in sprayable form or dispersed in an aqueous solution. Methods of making and using the compositions are also described.
    Type: Grant
    Filed: June 28, 2001
    Date of Patent: July 22, 2003
    Assignee: Bristol-Myers Squibb Company
    Inventors: Andrew D. Court, David D. Kershaw
  • Patent number: 6589982
    Abstract: Flavones with an isoprenyl group in the 8-position possess very good anti-inflammatory properties and can also be used to treat/prevent/cure skin-disorders when applied in food compositions.
    Type: Grant
    Filed: September 20, 2001
    Date of Patent: July 8, 2003
    Assignee: Lipton, division of Conopco, Inc.
    Inventors: Robert Mark Donovan, Martin Richard Green, Maria Catherine Tasker, Paula Rachel Yates
  • Patent number: 6579512
    Abstract: A pharmaceutical topical spray composition of corticosteroid, an alcohol, a propelant, and isopropyl myristate. A method for treating an inflammatory skin condition using the administration to the skin of a mammal of the pharmaceutical composition. The pharmaceutical composition is effective in the treatment of inflammatory skin conditions without the need for zinc pyrithione, undecylenic acid, or a detergent.
    Type: Grant
    Filed: June 15, 2001
    Date of Patent: June 17, 2003
    Inventor: Charles E. Crutchfield, III
  • Patent number: 6555105
    Abstract: Modifications to RANTES can result in the modified polypeptide acting as a RANTES or MIP-1&agr; antagonist. Such antagonists can be used in therapy to reduce inflammation. They are also useful in studying the properties of RANTES or of MIP-1&agr;.
    Type: Grant
    Filed: August 17, 2000
    Date of Patent: April 29, 2003
    Assignee: Glaxo Group Limited
    Inventors: Amanda E. I. Proudfoot, Timothy N. C. Wells
  • Patent number: 6551615
    Abstract: The present invention relates to a formulation and process for preparing dexibuprofen soft gelatin capsules comprising dexibuprofen dissolved in diethylene glycol monoethylether. The dexibuprofen-containing soft gelatin capsule includes a substantially clear solution of about 40% by weight of dexibuprofen, about 40% by weight of a solubilizer, about 0.8% to 5% be weight of surfactants, about 14% to 20% by weight of co-surfactants, about 2% by weight of a potassium salt generating species, and about 2% by weight of a viscosity imparter.
    Type: Grant
    Filed: October 18, 2001
    Date of Patent: April 22, 2003
    Assignee: M/s. Strides Arcolab Limited
    Inventors: V. S. Iyer, Shivaraj B. Katageri
  • Patent number: 6544530
    Abstract: The invention provides a composition of matter comprising a stable oil-in-glycerin emulstion containing at least one oil, at least one emulsifier and glycerin.
    Type: Grant
    Filed: January 22, 2001
    Date of Patent: April 8, 2003
    Assignee: J.P.M.E.D. Ltd.
    Inventor: Doron Friedman
  • Patent number: 6537977
    Abstract: A pharmaceutical composition, which contains glycosaminoglycan having at least one sulfate group or a pharmaceutically acceptable salt thereof, and an immunosuppressant.
    Type: Grant
    Filed: May 12, 1998
    Date of Patent: March 25, 2003
    Assignee: Seikagaku Corporation
    Inventors: Mamoru Kyogashima, Akira Asari
  • Patent number: 6517846
    Abstract: A cosmetic composition having effects suitable for sensitive skin, dry skin, roughening skin or skin with atopic dermatitis is provided. The cosmetic composition includes one or more compounds selected from N-long chain acylamino acids represented by formula (I): wherein n represents 1 or 2, and R represents a saturated or unsaturated hydrocarbon group of from 5 to 23 carbon atoms; and salts thereof.
    Type: Grant
    Filed: June 15, 2001
    Date of Patent: February 11, 2003
    Assignee: Kyowa Hakko Kogyo Co., Ltd.
    Inventor: Yoichiro Takekoshi
  • Patent number: 6518274
    Abstract: The invention relates to the use of cycloventabenzofuran derivatives for the production of a medicament for the treatment of nuclear factor of &kgr;B-dependent diseases.
    Type: Grant
    Filed: April 18, 2001
    Date of Patent: February 11, 2003
    Assignee: Bayer Aktiengesellschaft
    Inventors: Matthias Gehling, Jörg Baumgarten, Axel Kretschmer, Horst-Peter Antonicek, Peter Proksch, Bambang Wahyu Nugroho, Frank Bohnenstengel
  • Patent number: 6517847
    Abstract: A composition is provided that has a viscosity of less than about 15,000 cP and a pH of about 3.0 to 9.0 for treating a skin disorder in a human subject. The composition is a lotion that consists essentially of (a) a therapeutically-effective amount of at least one compound useful for treating such disorder, (b) a pharmaceutically-acceptable, lightly cross-linked polyacrylic acid polymer compatible with the compound, (c) a pharmaceutically acceptable base to adjust pH, (d) up to about 25% ww of at least one water miscible solvent, (e) optionally a preservative, (f) water, and (g) an oil phase component and suitable surfactant. The composition is useful for treating an inflammatory skin disorder, acne, or rosacea.
    Type: Grant
    Filed: March 8, 2002
    Date of Patent: February 11, 2003
    Assignee: Dow Pharmaceutical Sciences
    Inventors: Gordon J. Dow, Robert W. Lathrop, Debra A. Dow
  • Patent number: 6511670
    Abstract: Novel pharmaceutically/cosmetically-active (poly)thiaalkynoic compounds have the structural formula (I): R1—Y—CH2—C≡C—CH2—S—CH2—R2  (I) and are useful for the treatment of a wide variety of disease states, whether human or veterinary, for example inflammation disorders, as well as for the treatment of mammalian skin and hair conditions/disorders.
    Type: Grant
    Filed: April 13, 2000
    Date of Patent: January 28, 2003
    Assignee: Societe L'Oreal S.A.
    Inventors: Jean Maignan, Sylvie Genard, Serge Michel
  • Patent number: 6506387
    Abstract: The invention concerns a method for preparing aloin which consists in extracting from a substance containing aloe, in particular the yellow sap of aloe or a derived product, in the presence of an aliphatic diol or triol with low molecular weight, for instance glycerol or a glycol, followed by a purification by crystallization in an alcohol. The invention is useful for industrial preparation of aloin.
    Type: Grant
    Filed: February 16, 2001
    Date of Patent: January 14, 2003
    Assignee: Paxa N.V.
    Inventor: Avraham Cohen
  • Patent number: 6497877
    Abstract: Plasminogen activator acts as an anti-inflammatory agent by inhibiting generation of superoxide anion by a mechanism that is not related to L-arginine, is not dependent on thrombolytic activity, and is not a function of oxygen free radical scavenging. Moreover, in in vivo models of inflammation, treatment with plasminogen activator reduces edema without inhibiting neutrophil infiltration in in vivo models of inflammation.
    Type: Grant
    Filed: October 22, 1999
    Date of Patent: December 24, 2002
    Assignee: University Technology Corporation
    Inventors: Kathleen A. Stringer, Brooks M. Hybertson, John E. Repine, Joe M. McCord
  • Patent number: 6495514
    Abstract: The invention relates to a method for reducing inflammation in a subject by administering to the subject an effective amount of the compound having the structure I or II: wherein, R1 is C1-C10 branched or straight chain alkyl, aryl, an amino acid, or a peptide; and R2 is hydrogen or lower C1-C5 branched or straight alkyl, or the salt or ester thereof, wherein the stereochemistry about the carbon-carbon double bond is trans. The invention further relates to a method of inducing an analgesic effect by administering to a subject an effective amount of the compound having the structure I or II. The invention further relates to a compound having the structure II, wherein, R1 is an N-acyl amino acid or peptide, or the salt or ester thereof.
    Type: Grant
    Filed: January 21, 1998
    Date of Patent: December 17, 2002
    Assignee: Mercer University
    Inventors: Sheldon W. May, Stanley H. Pollock
  • Patent number: 6495596
    Abstract: The present invention comprises a group of related lipid molecules, and methods for their use, that maybe used to treat inflammation and certain inflammation related diseases. The group of related lipid molecules are capable of inhibiting certain enzyme systems including phospholipase A2, and cyclooxygenase-2. The group of related lipid molecules of the invention may be characterized by specific structural characteristics, or by specific biological activity, including inhibition of the previously listed enzymes.
    Type: Grant
    Filed: June 7, 2001
    Date of Patent: December 17, 2002
    Assignee: Biozibe Laboratories, Inc.
    Inventor: Brian Keller
  • Patent number: 6489367
    Abstract: The invention concerns semi-fluorinated alkanes of the general formulae RFRH or RFRHRF, RF being a linear or branched perfluoroalkyl group and RH being a linear or branched saturated (hydrocarbon)-alkyl group.
    Type: Grant
    Filed: May 15, 2001
    Date of Patent: December 3, 2002
    Inventor: Hasso Meinert
  • Patent number: 6485730
    Abstract: A single serving paraffin treatment system and method of application is disclosed which includes the steps of heating a small quantity of paraffin above its melting temperature, applying the paraffin to the hand or foot with a brush. The paraffin is contained in individualized disposable containers which are receivable in a heating unit. The heating unit preferably has at least two temperature settings.
    Type: Grant
    Filed: November 8, 2000
    Date of Patent: November 26, 2002
    Assignee: E.O.H. Industries, Inc.
    Inventors: Beth Ann Barrick Hickey, Rebecca Phillips Gentry, Royce E. Gentry
  • Patent number: 6475526
    Abstract: One aspect of the invention relates to anti-viral composition containing at least one zinc compound and at least one phenolic antioxidant (and optionally other ingredients such as at least one analgesic) at least one hydrocarbyl containing compound, and water. Another aspect of the invention relates to a method of treating lesionous symptoms of a viral infection involving applying an effective amount of the zinc containing anti-viral composition to the lesions.
    Type: Grant
    Filed: June 5, 2001
    Date of Patent: November 5, 2002
    Inventor: Jeffrey B. Smith
  • Patent number: 6476052
    Abstract: Substituted 1-oxo-2-(2,6-dioxopiperidin-3-yl)isoindolines are useful in treating inflammation, inflammatory disease, autoimmune disease, and oncogenic or cancerous conditions in a mammal. Typical embodiments are 1-oxo-2-(2,6-dioxopiperidin-3yl)4-aminoisoindoline and 1-oxo-2-(2,6-dioxo-3-methylpiperidin-3-yl)aminoisoindoline.
    Type: Grant
    Filed: August 7, 2000
    Date of Patent: November 5, 2002
    Assignee: Celgene Corporation
    Inventors: George W. Muller, David I. Stirling, Roger Shen-Chu Chen
  • Patent number: 6476002
    Abstract: A method of treating a chronic inflammatory disease such as rheumatoid arthritis or psoriasis includes treating a patient with a toxin derived from Group B &bgr;-hemolytic Streptococcus bacteria. The purified GBS toxin, or CM101, may be administered. intravenously to the patient in repeated doses.
    Type: Grant
    Filed: October 28, 1999
    Date of Patent: November 5, 2002
    Assignee: Vanderbilt University
    Inventors: Carl G. Hellerqvist, Barbara D. Wamil
  • Patent number: 6471973
    Abstract: The invention relates to a flavonoid ester. This flavonoid ester results from the reaction product of at least one flavonoid selected from the group consisting of a flavonoid with a ketone group in the 4-position, a salt, ester or ether of such a flavonoid, and a C-heteroside and/or O-heteroside derivative of such a flavonoid, with the proviso that this flavonoid contains at least one free alcohol group, with an organic monoacid having from 3 to 30 carbon atoms. These flavonoid esters constitute useful active principles for the manufacture of cosmetic, dermopharmaceutical, pharmaceutical, dietetic or agri-foodstuff compositions.
    Type: Grant
    Filed: April 10, 2001
    Date of Patent: October 29, 2002
    Assignee: Coletica
    Inventors: Eric Perrier, Anne-Marie Mariotte, Ahcène Boumendjel, Delphine Bresson-Rival
  • Patent number: 6462016
    Abstract: There are provided a method to screen agonist or antagonist of the maxadilan receptor participating in vasodilating action, wherein a receptor of maxadilan is used, compounds which specifically bind to the receptor, and a tissue preparation having the receptor. The compounds are variants of maxadilan from the salivary glands of the sand fly.
    Type: Grant
    Filed: November 13, 1997
    Date of Patent: October 8, 2002
    Assignees: Shiseido Company, Ltd., The General Hospital Corporation
    Inventors: Kawori Wakita, Osamu Moro, Manami Ohnuma, Ethan A. Lerner, Masahiro Tajima
  • Patent number: 6461619
    Abstract: The present invention is directed to methods that can be used in the treatment of wounds, burns, and photodamaged skin. Methods can be used for both humans and animals and involve the administration of compositions containing selegiline and/or desmethylselegiline.
    Type: Grant
    Filed: September 15, 2000
    Date of Patent: October 8, 2002
    Assignee: Somerset Pharmaceuticals, Inc.
    Inventor: Mark G. Resnick
  • Patent number: 6458837
    Abstract: The invention discloses stable diesters of chelating agents of divalent metal ions, processes for their preparation and pharmaceutical compositions thereof. Most preferred compounds according to the present invention are stable lipophilic diesters comprising a covalent conjugate of a BAPTA and a pharmaceutically acceptable alcohol. The diesters are useful in a method for treating a condition or disease related to an excess of divalent metal ions, and in particular for the treatment of a condition or disease related to elevated levels of intracellular calcium ions, such as in brain or cardiac ischemia, stroke, epilepsy, Alzheimer's disease or cardiac arrhythmia and in open heart surgery.
    Type: Grant
    Filed: March 27, 2000
    Date of Patent: October 1, 2002
    Assignee: D-Pharm Ltd.
    Inventors: Alexander Kozak, Israel Shapiro
  • Patent number: 6455497
    Abstract: The invention provides methods and materials related to the treatment of inflammatory diseases such as rheumatoid arthritis. Specifically, the invention provides methods and materials for treating inflammation by reducing production of an inflammatory cytokine such as IFN-&ggr;, IL-, and TNF-&agr;. The invention also provides methods and materials for identifying reagents that can be used to treat inflammatory diseases. Specifically, the invention provides non-human animals containing human synovial tissue as well as methods for using such non-human animals to determine the influence of various test reagents on the inflamed state of human synovial tissue.
    Type: Grant
    Filed: November 30, 2000
    Date of Patent: September 24, 2002
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Jorg J. Goronzy, Cornelia M. Weyand
  • Patent number: 6451352
    Abstract: The invention concerns the use of iso-osmotic saline solutions in particular obtained from sea water, to obtain a medicine designed for a treatment preventing and limiting the release of chemical mediators responsible for causing inflammatory phenomena in the human respiratory tracts.
    Type: Grant
    Filed: May 24, 2001
    Date of Patent: September 17, 2002
    Assignee: Laboratoires Goemar S.A.
    Inventors: Jean-Claude Yvin, Olivier Tabary, Jacky Jacquot, Edith Puchelle
  • Patent number: 6444699
    Abstract: An ascorbic acid-based composition and related method for the treatment of aging or photo-damaged skin is disclosed. The composition includes water and ascorbic acid, at least a portion of which has generally been pretreated by being dissolved under relatively high temperature and concentration conditions. The composition typically includes at least about 5.0% (w/v) ascorbic acid and may advantageously be formulated to have a pH above 3.5. Generally, the composition also includes non-toxic zinc salt, tyrosine compound, and/or pharmaceutically acceptable carrier. In addition, the composition may include an anti-inflammatory compound, such as aminosugar and/or sulfur-containing anti-inflammatory compound. The topical composition may be in the form of a serum, a hydrophilic lotion, an ointment, a cream, or a gel.
    Type: Grant
    Filed: December 7, 2000
    Date of Patent: September 3, 2002
    Assignee: Bioderm, Inc.
    Inventor: Lorraine Faxon Meisner
  • Patent number: 6444709
    Abstract: The invention relates to novel heteroethynylenic compounds having the general formula (I): as well as to the use of these compounds in pharmaceutical compositions intended for use in human or veterinary medicine (dermatological, rheumatic, respiratory, cardiovascular and ophthalmological complaints in particular), or alternatively in cosmetic compositions.
    Type: Grant
    Filed: February 7, 2000
    Date of Patent: September 3, 2002
    Assignee: Galderma Research & Development S.N.C.
    Inventors: Philippe Diaz, Jean-Michel Bernardon
  • Patent number: 6432434
    Abstract: The administration of &agr;-lipoic acid (&agr;LA) and dihydrolipoic acid (DHL) both as a preventive measure before exposure to conditions which may cause damage, such as rapid changes in atmospheric pressure, and as a means of preventing or ameliorating damage arising from such injury provides benefits not currently available. The active agents may be administered systemically or to the injured tissue. For example, when there is spinal cord injury, the active agents may be administered intrathecally.
    Type: Grant
    Filed: April 21, 2000
    Date of Patent: August 13, 2002
    Assignee: The United States of America as represented by the Secretary of the Army
    Inventors: James L. Meyerhoff, Joseph Long, Michael Koenig
  • Publication number: 20020106384
    Abstract: Cosmetic compositions and methods for lightening the skin using a low molecular weight fraction of gugulipid in combination with an alpha-hydroxy acid, or niacinamide, or L-phenylalanine.
    Type: Application
    Filed: December 7, 2000
    Publication date: August 8, 2002
    Inventors: Kelly Hua Zhang, Prasanna Satpute, Koichi Iwata, Michael Tallman